en · de · es · pt
sermorelin-notes.peptides7250.com › Info › Tirzepatide �ˆ†子背景与靶点 — Complete Guide

Tirzepatide �ˆ†子背景与靶点 — Complete Guide

By Editorial Desk · published 2025-07-02 · last reviewed 2025-08-19 · Info

Everything below concerns incretin receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Updated 2025-08-19. Numbers and descriptions here follow the published literature rather than marketing material.

Tirzepatide 分子背景与靶点

该化合物的名称与结构由国际非专利名称体系统一维持,不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。

当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体,而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录,可作为分析检测和质量研究的参照。

Dual Incretin Receptor Pharmacology

Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.

At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.

Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.

Tirzepatide at a glance

PropertyValueNotes
分子类型合成修饰肽39 个氨基酸,含脂肪酸侧链
受体靶点GIP 与 GLP-1 受体双重激动剂
分子量约 4.8 kDa以游离肽计
外观白色至类白色粉末冻干形态常见
溶解性可溶于水及水性缓冲液溶解后宜低温保存

Molecular Background and Dual Receptor Action

Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.

Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.

Related pages on this site

Tirzepatide Pharmacology and Development History

Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.

Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.

The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.

Molecular Background and Receptor Pharmacology

The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.

After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.

Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.

Analytical Methods And Storage Stability

Cold-chain handling is standard for formulated product, with dry powder stored frozen and ready-to-use solutions refrigerated. Light exposure is minimized because photodegradation of certain amino acid side chains is possible. Shipping and temperature-excursion studies are used to establish whether short deviations affect quality attributes. Documentation supplied with research material usually includes a certificate of analysis listing purity, identity confirmation, and water or residual solvent content. Users are expected to confirm that material meets the stated specification before use.

Identity and purity of tirzepatide are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Because the molecule carries several modifications, gradient conditions are adjusted to resolve the intact peptide from deamidation and oxidation products. Enzymatic digestion followed by peptide mapping confirms the primary sequence and locates specific modifications. Quantitation in biological matrices typically uses liquid chromatography with tandem mass spectrometry after solid-phase extraction. Immunoassays are used less often, since antibody cross-reactivity with closely related peptides can bias results.

The peptide shares degradation routes common to modified peptides: deamidation of asparagine and glutamine residues, oxidation of methionine, and backbone hydrolysis under extreme pH. Lyophilized material is generally more stable than a solution, and residual water content directly affects the rate of hydrolysis. In liquid form, aggregation and visible particles can appear after agitation or repeated freeze-thaw cycles. Stability studies therefore track monomer content, aggregate content, and potency over months under defined temperature and humidity.

Background from the literature

Korolev's conversion of his surplus Vostok capsules to the Voskhod spacecraft allowed the Soviet space program to beat the Gemini program in achieving the first spaceflight with a multi-person crew, and the first "spacewalk". Gemini took a year longer than planned to make its first flight, so Voskhod 1 became the first spaceflight with a three-person crew on October 12, 1964. The USSR touted another "technological achievement" during this mission: it was the first space flight during which cosmonauts performed in a shirt-sleeve-environment. However, flying without spacesuits was not due to safety improvements in the Soviet spacecraft's environmental systems; rather this was because the craft's limited cabin space did not allow for spacesuits. Flying without spacesuits exposed the cosmonauts to significant risk in the event of potentially fatal cabin depressurization. This was not repeated until the US Apollo Command Module flew in 1968; the command module cabin was designed to transport three astronauts in a low pressure, pure oxygen shirt-sleeve environment while in space. On March 18, 1965, about a week before the first piloted Project Gemini space flight, the USSR launched the two-cosmonaut Voskhod 2 mission with Pavel Belyayev and Alexei Leonov. Voskhod 2's design modifications included the addition of an inflatable airlock to allow for extravehicular activity (EVA), also known as a spacewalk, while keeping the cabin pressurized so that the capsule's electronics would not overheat. Leonov performed the first-ever EVA as part of the mission.

While building up the country's nuclear program, increasing Islamisation, and the rise of a homegrown conservative philosophy, Pakistan helped subsidise and distribute US resources to factions of the mujahideen against the USSR's intervention in communist Afghanistan. Pakistan's North-West Frontier Province became a base for the anti-Soviet Afghan fighters, with the province's influential Deobandi ulama playing a significant role in encouraging and organising the 'jihad'. President Zia died in a plane crash in 1988, and Benazir Bhutto, daughter of Zulfikar Ali Bhutto, was elected as the country's first female Prime Minister. The PPP was followed by conservative Pakistan Muslim League (N) (PML (N)), and over the next decade the leaders of the two parties fought for power, alternating in office. This period is marked by prolonged stagflation, political instability, corruption, misgovernment, geopolitical rivalry with India, and the clash between left-wing and right-wing ideologies. As PML (N) secured a supermajority in elections in 1997, Nawaz Sharif authorised nuclear testings, as a retaliation to the second nuclear tests conducted by India in May 1998.

Other studies found that, in Tanzania, skin bleaching has been regularly practiced by middle and working classes, as light skin was perceived to facilitate social mobility. Skin whitening practices in several other African countries increased following the onset of independence movements against European colonial rule. Maya Allen attributed this to the increased flow of European products and commercial influence into colonized regions. Several historians have suggested that the increased prevalence of skin whitening in "the Global South" is potentially tied to both precolonial notions of beauty and post-colonial hierarchies of race.

Sources: en.wikipedia.org

Reference notes

== Epidemiology == Cholecystitis accounts for 3–10% of cases of abdominal pain worldwide. Cholecystitis caused an estimated 651,829 emergency department visits and 389,180 hospital admissions in the US in 2012. The 2012 US mortality rate was 0.7 per 100,000 people. The frequency of cholecystitis is highest in people age 50–69 years old.

The one-stepwise pyrolysis experiment showed different results for the CO2 and N2 environments. During this process the evolution of 5 different notable gases were observed. Hydrogen, Methane, Ethane, Carbon Dioxide, and Ethylene all are produced when the thermolytic rate of TLW began to be retarded at greater than or equal to 500 °C. Thermolytic rate begins at the same temperatures for both the CO2 and N2 environment but there is higher concentration of the production of Hydrogen, Ethane, Ethylene, and Methane in the N2 environment than that in the CO2 environment. The concentration of CO in the CO2 environment is significantly greater as temperatures increase past 600 °C and this is due to CO2 being liberated from CaCO3 in TLW. This significant increase in CO concentration is why there is lower concentrations of other gases produced in the CO2 environment due to a dilution effect. Since pyrolysis is the re-distribution of carbons in carbon substrates into three pyrogenic products. The CO2 environment is going to be more effective because the CO2 reduction into CO allows for the oxidation of pyrolysates to form CO. In conclusion the CO2 environment allows a higher yield of gases than oil and biochar. When the same process is done for TSW the trends are almost identical therefore the same explanations can be applied to the pyrolysis of TSW. Harmful chemicals were reduced in the CO2 environment due to CO formation causing tar to be reduced.

== Environmental Impact == Parcel to pallet sized insulated shipping containers have historically been single-use products due to the low-cost material composition of EPS and water-based gel packs. The insulation material typically finds its way into landfill streams as it is not readily recyclable in the United States. The development of reusable high-performance shipping containers have been shown to reduce packing waste by 95% while also contributing significant savings to other environmental pollutants.

==== F ==== Fesikh – a traditional Egyptian fish dish consisting of fermented salted and dried gray mullet, of the mugil family, a saltwater fish that lives in both the Mediterranean and the Red Seas.

Sources: en.wikipedia.org

Frequently asked questions

Tirzepatide 属于哪一类分子?

它属于合成修饰肽,同时激动 GIP 与 GLP-1 两种肠促胰素受体。这类分子通常被称为双重肠促胰素受体激动剂,与选择性 GLP-1 激动剂在靶点范围上不同。

为什么它只需每周给药一次?

分子上的脂肪酸侧链使其与血浆白蛋白结合增强,显著延长循环半衰期。半衰期延长后,稳定血药浓度可在较长的给药间隔内维持,因此常见用法为每周一次。

双靶点设计的意义是什么?

同时激活两条肠促胰素通路可能在胰岛素分泌、胃排空和食欲调节上产生叠加效应。与单靶点相比,临床研究中观察到的血糖与体重变化幅度通常更明显,但各通路的具体贡献比例尚无定论。

What class of compound is tirzepatide?

It is a synthetic peptide and a dual agonist of two incretin receptors. It is not a small molecule, and it is not structurally related to the older single-receptor peptide agonists.

Network